Healthcare

Chronic Cough Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Chronic Cough Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Chronic Cough Market:

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

According to The Business Research Company’s Chronic Cough Global Market Report 2024, The chronic cough market size has grown strongly in recent years. It will grow from $7.5 billion in 2023 to $8.16 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to prevalence of underlying respiratory conditions, environmental factors and air pollution, smoking and tobacco use, respiratory infections, allergies and environmental sensitivities.

The chronic cough market size is expected to see strong growth in the next few years. It will grow to $11.48 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to emerging therapies targeting specific pathways, increasing understanding of reflux-related cough, global efforts in smoking cessation, environmental and occupational health policies. Major trends in the forecast period include advancements in diagnostic technologies, patient-centric approaches, therapeutic innovations in neurogenic cough, telehealth for chronic cough management, research on central sensitization.

The rise in the prevalence of cough is expected to propel the growth of the chronic cough market going forward. Cough refers to a reflex action that, frequently in response to irritation, mucus, or foreign objects, helps clear the airways by ejecting air forcefully from the lungs. A persistent cough that lasts for at least eight weeks is considered chronic. Therefore, when the incidence of cough rises, so do the cases of chronic cough. For instance, in March 2022, according to the Florida Health, a US-based Department of Healthcare, in the US total of 80 patients were found in 2021, for incidences of 41.0 and 1.4 per 100,000 years, respectively. There were 28 pertussis cases recorded in 2023 among 13 countries. Furthermore, in March 2022, according to the Statens Serum Institut, a Denmark-based department of disease surveillance, the number of pertussis cases recorded increased by 41% from November 2022 to April 2023, compared to November 2021–April 2022 in Denmark. Therefore, the rise in the prevalence of cough is driving the growth of the chronic cough market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12109&type=smp

The chronic cough market covered in this report is segmented –

1) By Drug Class: Antihistamines, Corticosteroids, Decongestants, Combination Drug, Antibiotics, Acid Blockers, Other Drug Classes

2) By Route Of Administration: Oral, Inhalational, Injectable, Other Route of Administrations

3) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Major companies operating in the chronic cough market are concentrating on creating innovative products such as cough syrup to strengthen their position in the market. Cough syrup is used to treat upper respiratory allergies and common cold which contain non-opioid cough suppressants that acts on the cough center, a specific area of the brain, to assist stop coughing. For instance, in September 2021, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company launched Chericof 12. Chericof 12 is a new cough remedy formulation and the first prescription cough syrup that offers 12-hour relief. Chericof 12 is produced with the use of Polistirex technology, which provides a longer-lasting medication release and helps to improve patient compliance by preventing dosage modifications. Using Polistirex technology, the formulation complexes two medications, chlorpheniramine maleate and dextromethorphan hydrobromide. As a result, the medication is released gradually, helping to relieve coughing for an extended period of time.

The chronic cough market report table of contents includes: